BRD4-mediated repression of p53 is a target for combination therapy in AML.
Nat Commun. 2021 Jan 11;12(1):241. doi: 10.1038/s41467-020-20378-8.
Nat Commun. 2021.
PMID: 33431824
Free PMC article.